Oramed Pharmaceuticals
ORMP
$2.30
Share price
-1.29%
Change (1 day)
-36.64%
Change (1 year)
Categories
P/S ratio for Oramed Pharmaceuticals (ORMP)
P/S ratio as of May 2024 (TTM): 70.6
According to Oramed Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 70.6458. At the end of 2023 the company had a P/S ratio of 69.5.
P/S ratio history for Oramed Pharmaceuticals from 2009 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 69.5 | -60.05% |
| 2022 | 174 | -35.72% |
| 2021 | 271 | 623.54% |
| 2020 | 37.4 | 31.86% |
| 2019 | 28.4 | 0.56% |
| 2018 | 28.2 | -46.97% |
| 2017 | 53.2 | -18.27% |
| 2016 | 65.1 | |
| 2015 | N/A | |
| 2014 | N/A | |
| 2013 | N/A | |
| 2012 | N/A | |
| 2011 | N/A | |
| 2010 | N/A | |
| 2009 | N/A |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Novo Nordisk NVO | 16.7 | -76.34% | 🇩🇰 Denmark |
 Sanofi SNY | 2.44 | -96.55% | 🇫🇷 France |
 Ultragenyx RARE | 8.16 | -88.45% | 🇺🇸 USA |
 Lexicon Pharmaceuticals
LXRX | 552 | 681.35% | 🇺🇸 USA |
 Compugen CGEN | 5.73 | -91.89% | 🇮🇱 Israel |